Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór w stadium T2-T4a bez przerzutów do węzłów chłonnych lub z przerzutami do węzłów N0/N1, albo stadium T1 z przerzutami do węzłów N1
- •Zaplanowana operacja usunięcia pęcherza moczowego
- •Pacjent nie otrzymywał wcześniej chemioterapii lub immunoterapii z powodu raka pęcherza
- •Ogólny stan zdrowia pozwalający na udział w badaniu (skala ECOG 0-1)
- •Oczekiwana długość życia co najmniej 12 tygodni od pierwszej dawki leku
✗ Disqualifies
- •Przerzuty do węzłów chłonnych (N2-N3) lub przerzuty odległe (M1)
- •Nowotwór niemożliwy do operacyjnego usunięcia lub przyросły do ścian miednicy
- •Wcześniejsze leczenie podobnymi lekami immunologicznymi (poza szczepionką BCG)
- •Stosowanie leków hamujących układ odpornościowy w ciągu 14 dni przed badaniem
- •Inne leki niezgodne z planowaną chemioterapią
- •Nieskontrolowane poważne schorzenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (59)
Research Site
Chermside, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Heidelberg, Australia
Research Site
Hong Kong, Australia
Research Site
Kogarah, Australia
Research Site
Macquarie University, Australia
Research Site
Murdoch, Australia
Research Site
Port Macquarie, Australia
Research Site
St Leonards, Australia
Research Site
Barretos, Brazil
Research Site
Jaú, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Hamilton, Canada
Research Site
London, Canada
Research Site
Ottawa, Canada
Research Site
Montreal, Canada
Research Site
Québec, Canada
Research Site
Sherbrooke, Canada
Research Site
Angers, France
Research Site
Angers, France
Research Site
Bordeaux, France
Research Site
Chambray-lès-Tours, France
Research Site
Dijon, France
Research Site
Lille, France
Research Site
Lyon, France
Research Site
Marseille, France
Research Site
Montpellier, France
Research Site
Nice, France
Research Site
Nîmes, France
Research Site
Paris, France
Research Site
Paris, France
Research Site
Pierre-Bénite, France
Research Site
Poitiers, France
Research Site
Quint-Fonsegrives, France
Research Site
Rennes, France
Research Site
Rouen, France
Research Site
Strasbourg, France
Research Site
Suresnes, France
Research Site
Florence, Italy
Research Site
Orbassano, Italy
Research Site
Roma, Italy
Research Site
Amsterdam, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Girona, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
Lugo, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Santiago de Compostela, Spain
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.